Kidney disease and multiple myeloma

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 11, 2013, Pages 2007-2017

  Heher, Eliot C ^a   Rennke, Helmut G ^b   Laubach, Jacob P ^c   Richardson, Paul G ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID P COMPONENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PARAPROTEIN; THALIDOMIDE;

AMYLOIDOSIS; ARTICLE; BONE MARROW SUPPRESSION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTRON MICROSCOPY; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIGHT CHAIN DEPOSITION DISEASE; LOW DRUG DOSE; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PROGNOSIS; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL;

ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULINS; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PLASMA EXCHANGE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84887282355     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12231212     Document Type: Article

References (100)

1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT: Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23: 9219-9226, 2005
2. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J; The Nordic Myeloma Study Group: Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. Eur J Haematol 53: 207-212, 1994
3. Knudsen LM, Hjorth M, Hippe E; Nordic Myeloma Study Group: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol 65: 175-181, 2000
4. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG: Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single centre. Nephrol Dial Transplant 25: 419-426, 2010
5. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003
6. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004
7. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362-1369, 2006
8. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011
9. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI: The growth fraction of human myeloma cells. Blood 57: 333-338, 1981
10. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome. Blood 109: 3489-3495, 2007
11. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understandingmultiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598, 2007
12. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD: Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 20: 2055-2064, 2009
13. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH: Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 64: 527-537, 1991
14. Komatsuda A, Masai R, Ohtani H, Togashi M, Maki N, Sawada K, Wakui H: Monoclonal immunoglobulin deposition disease associatedwith membranous features. Nephrol Dial Transplant 23: 3888-3894, 2008
15. Herlitz LC, Roglieri J, Resta R, Bhagat G, Markowitz GS: Light chain proximal tubulopathy. Kidney Int 76: 792-797, 2009
16. Lacy MQ, Gertz MA: Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am 13: 1273-1280, 1999
17. Gu X, Herrera GA: Light-chain-mediated acute tubular interstitial nephritis: A poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 130: 165-169, 2006
18. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128: 875-879, 2004
19. Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, Ronco P: Renal lesions associated with IgM-secreting monoclonal proliferations: Revisiting the disease spectrum. Clin J Am Soc Nephrol 3: 1339-1349, 2008
20. Zickerman AM, Allen AC, Talwar V, Olczak SA, Brownlee A, Holland M, Furness PN, Brunskill NJ, Feehally J: IgA myeloma presenting as Henoch-Schönlein purpura with nephritis. Am J Kidney Dis 36: E19, 2000
21. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, Leung N: Renal monoclonal immunoglobulin deposition disease: A report of 64 patients from a single institution. Clin J Am Soc Nephrol 7: 231-239, 2012
22. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12: 1558-1565, 2001
23. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA; International Kidney and Monoclonal Gammopathy Research Group: Monoclonal gammopathy of renal significance: WhenMGUS is no longer undetermined or insignificant. Blood 120: 4292-4295, 2012
24. Merlini G, Stone MJ:Dangerous small B-cell clones. Blood 108: 2520-2530, 2006
25. Rabb H, Gunasekaran H, Gunasekaran S, Saba SR: Acute renal failure from multiple myeloma precipitated by ACE inhibitors. Am J Kidney Dis 33: E5, 1999
26. Hanawa S, Akimoto T, Uehara E, Inoue M, Imai T, Kotoda A, Yoshizawa H, Matsuyama T, Ueda M, Saito O, Hamano Y, YumuraW, Ozawa K, Muto S, Kusano E: Renal failure caused by plasma cell infiltration in multiple myeloma. Clin Exp Nephrol 15: 586-590, 2011
27. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, PaleckiW, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281-289, 2003
28. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with highdose pamidronate. J Am Soc Nephrol 12: 1164-1172, 2001
29. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P: The biology of immunoglobulin free light chains and kidney injury. Kidney Int 79: 1289-1301, 2011
30. Christensen EI, Birn H: Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 280: F562-F573, 2001
31. Sirac C, Bridoux F, Carrion C, Devuyst O, Fernandez B, Goujon JM, El Hamel C, Aldigier JC, Touchard G, Cogné M: Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome. Blood 108: 536-543, 2006
32. Sengul S, Zwizinski C, Batuman V: Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 284: F1245-F1254, 2003
33. Kominami E, Tsukahara T, Bando Y, Katunuma N: Distribution of cathepsins B and H in rat tissues and peripheral blood cells. J Biochem 98: 87-93, 1985
34. Wang PX, Sanders PW: Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 18: 1239-1245, 2007
35. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324: 1845-1851, 1991
36. Vidal R, Goñi F, Stevens F, Aucouturier P, Kumar A, Frangione B, Ghiso J, Gallo G: Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: Potential effects on aberrant protein conformation and deposition. AmJ Pathol 155: 2009-2017, 1999
37. Solomon A, Frangione B, Franklin EC: Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 70: 453-460, 1982
38. Hurle MR, Helms LR, Li L, Chan W, Wetzel R: A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 91: 5446-5450, 1994
39. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 84: 440-451, 2004
40. Ramirez-Alvarado M, Ward CJ, HuangBQ, Gong X, Hogan MC, Madden BJ, Charlesworth MC, Leung N: Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al). PLoS One 7: e38061, 2012
41. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002
42. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673-680, 2001
43. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, MeadG: Serumfree light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9: 11, 2008
44. Lachmann HJ, Hawkins PN: Novel pharmacological strategies in amyloidosis. Nephron Clin Pract 94: c85-c88, 2003
45. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B: High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110: 827-832, 2007
46. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P: Quantitative assessment of serum and urinary polyclonal free light chains in patientswith chronic kidney disease. Clin J Am Soc Nephrol 3: 1684-1690, 2008
47. Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B: Risk of antigen excess in serum free light chain measurements. Clin Chem 53: 1985-1986, 2007
48. Vermeersch P, Marien G, Bossuyt X: More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B-cell disorders in routine clinical practice. Br J Haematol 143: 143-145, 2008
49. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M: Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25: 1993-1999, 2007
50. Pozzi C, D'AmicoM, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F: Light chain deposition disease with renal involvement: Clinical characteristics and prognostic factors. Am J Kidney Dis 42: 1154-1163, 2003
51. Izzedine H, Camous L, Bourry E, Azar N, Leblond V, Deray G: Make your diagnosis. Multiple myeloma-associated with spurious hyperphosphatemia. Kidney Int 72: 1035-1036, 2007
52. Nasr SH, Galgano SJ, Markowitz GS, Stokes MB, D'Agati VD: Immunofluorescence on pronase-digested paraffin sections: A valuable salvage technique for renal biopsies. Kidney Int 70: 2148-2151, 2006
53. Nasr SH, Markowitz GS, Reddy BS, Maesaka J, Swidler MA, D'Agati VD: Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int 69: 772-775, 2006
54. Sanders PW, Booker BB, Bishop JB, Cheung HC: Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 85: 570-576, 1990
55. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008
56. Torra R, Bladé J, Cases A, López-Pedret J, Montserrat E, Rozman C, Revert L: Patients with multiple myeloma requiring longterm dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91: 854-859, 1995
57. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N: Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22: 1129-1136, 2011
58. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, IrwinD, Stadtmauer EA, Facon T, Harousseau JL, Ben-YehudaD, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, EsseltineDL, Anderson KC: Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia 22: 842-849, 2008
59. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 103: 1195-1200, 2005
60. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S: Activity and safety of bortezomib in multiplemyeloma patients with advanced renal failure: A multicenter retrospective study. Blood 109: 2604-2606, 2007
61. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl JMed 359: 906-917, 2008
62. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005
63. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792, 2007
64. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S: The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 113: 3040-3049, 2009
65. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC: The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 21: 1007-1034, 2007
66. Ludwig H, Drach J, Graf H, Lang A, Meran JG: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92: 1411-1414, 2007
67. Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N: Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 28: 4635-4641, 2010
68. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos MA: Treatment of patients with multiple myeloma complicated by renal failurewith bortezomib-based regimens. Leuk Lymphoma 49: 890-895, 2008
69. Ostermann E, Schrattbauer K, Ludwig H, Graf H: Rapid recovery of kidney function in patients with multiple myeloma under bortezomib-combination therapy. Available at: http:// www.asn-online.org/education_and_meetings/renal_week/ archives/. Accessed December 2009
70. Nozza A, Siracusano L, Armando S: Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther 28: 953-959, 2006
71. Mohrbacher A, Levine AM: Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 23: 6714, 2005
72. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120: 2817-2825, 2012
73. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS: An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomibnaive patients with relapsed and/or refractory multiplemyeloma. Blood 119: 5661-5670, 2012
74. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R: Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety [published online ahead of print January 31, 2013]. Leukemia doi:10.1038/leu.2013.29
75. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1485-1493, 2008
76. DimopoulosMA, Kastritis E, Rajkumar SV: Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22: 1343-1353, 2008
77. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47: 1466-1475, 2007
78. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M: Lenalidomideinduced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-nai{dotless}ve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 138: 640-643, 2007
79. Harris E, Behrens J, SamsonD, Rahemtulla A, Russell NH, Byrne JL: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 122: 160-161, 2003
80. Durie BG, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 307: 1689-1692, 1982
81. GaballaMR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG: Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 5: 51-66, 2012
82. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92: 546-549, 2007
83. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J: Treatment of multiple myeloma. Blood 103: 20-32, 2004
84. Sirohi B, Powles R, Harousseau JL, Anderson KC: The evolving background for high-dose treatment for myeloma. Bone Marrow Transplant 40: 1097-1100, 2007
85. Leung N, Slezak JM, Bergstralh EJ, Dispenzieri A, Lacy MQ, Wolf RC, Gertz MA: Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 45: 102-111, 2005
86. Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR, Textor SC, Lacy MQ, Litzow MR, Cosio FG, Larson TS, GertzMA, Stegall MD: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. AmJ Transplant 5: 1660-1670, 2005
87. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omede P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110-1120, 2007
88. Heher EC, Spitzer TR: Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol 30: 602-614, 2010
89. Harousseau JL, Moreau P: Autologous hematopoietic stemcell transplantation for multiple myeloma. N Engl J Med 360: 2645-2654, 2009
90. Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, Kraus A, Bonnefoix T, McAfee S, Power K, Kattleman K, Colvin RB, Sachs DH, Cosimi AB, Sykes M: Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. AmJ Transplant 6: 2121-2133, 2006
91. Cserti C, Haspel R, Stowell C, Dzik W: Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 47: 511-514, 2007
92. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73: 1282-1288, 2008
93. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN; Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 143: 777-784, 2005
94. Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D: Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 27: 3823-3828, 2012
95. Mehta S, Shtaynberg N, Goldman M, Asti D, Kiroycheva M, Pepe J: Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy. Hematology 17: 229-231, 2012
96. Short AK, O'Donoghue DJ, Riad HN, Short CD, Roberts IS: Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 21: 237-240, 2001
97. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC: Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 43: 147-153, 2004
98. Heher EC, Spitzer TR, Goes NB: Light chains: Heavy burden in kidney transplantation. Transplantation 87: 947-952, 2009
99. Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N: Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol 35: 365-371, 2012
100. Herrmann SM, GertzMA, StegallMD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N: Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 26: 2032-2036, 2011